Annual Operating Expenses
$402.99 M
+$6.38 M+1.61%
December 31, 2023
Summary
- As of February 12, 2025, PCRX annual total operating expenses is $402.99 million, with the most recent change of +$6.38 million (+1.61%) on December 31, 2023.
- During the last 3 years, PCRX annual operating expenses has risen by +$142.18 million (+54.52%).
- PCRX annual operating expenses is now at all-time high.
Performance
PCRX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$107.76 M
+$4.97 M+4.84%
September 30, 2024
Summary
- As of February 12, 2025, PCRX quarterly total operating expenses is $107.76 million, with the most recent change of +$4.97 million (+4.84%) on September 30, 2024.
- Over the past year, PCRX quarterly operating expenses has increased by +$4.66 million (+4.52%).
- PCRX quarterly operating expenses is now at all-time high.
Performance
PCRX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
PCRX Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +1.6% | +4.5% |
| 3 y3 years | +54.5% | +7.6% |
| 5 y5 years | +73.0% | +7.6% |
PCRX Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.1% | at high | +43.1% |
| 5 y | 5-year | at high | +54.5% | at high | +82.9% |
| alltime | all time | at high | +1512.3% | at high | +1806.2% |
Pacira BioSciences Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $107.76 M(+4.8%) |
| Jun 2024 | - | $102.79 M(-1.7%) |
| Mar 2024 | - | $104.59 M(+5.0%) |
| Dec 2023 | $402.99 M(+1.6%) | $99.59 M(-3.4%) |
| Sep 2023 | - | $103.10 M(+5.2%) |
| Jun 2023 | - | $98.00 M(-4.2%) |
| Mar 2023 | - | $102.31 M(+6.8%) |
| Dec 2022 | $396.60 M(+47.7%) | $95.80 M(+0.8%) |
| Sep 2022 | - | $95.01 M(-10.0%) |
| Jun 2022 | - | $105.61 M(+5.4%) |
| Mar 2022 | - | $100.19 M(+33.0%) |
| Dec 2021 | $268.44 M(+2.9%) | $75.32 M(+22.7%) |
| Sep 2021 | - | $61.40 M(-6.0%) |
| Jun 2021 | - | $65.35 M(-1.5%) |
| Mar 2021 | - | $66.37 M(-5.4%) |
| Dec 2020 | $260.80 M(-6.4%) | $70.13 M(+1.4%) |
| Sep 2020 | - | $69.18 M(+17.4%) |
| Jun 2020 | - | $58.93 M(-5.8%) |
| Mar 2020 | - | $62.57 M(-17.5%) |
| Dec 2019 | $278.60 M(+19.6%) | $75.84 M(+4.8%) |
| Sep 2019 | - | $72.35 M(+5.3%) |
| Jun 2019 | - | $68.72 M(+11.4%) |
| Mar 2019 | - | $61.69 M(+4.9%) |
| Dec 2018 | $232.95 M(+6.5%) | $58.82 M(-0.4%) |
| Sep 2018 | - | $59.08 M(+4.6%) |
| Jun 2018 | - | $56.49 M(-3.6%) |
| Mar 2018 | - | $58.57 M(+19.0%) |
| Dec 2017 | $218.78 M(+10.3%) | $49.21 M(-6.1%) |
| Sep 2017 | - | $52.42 M(-10.3%) |
| Jun 2017 | - | $58.41 M(-0.6%) |
| Mar 2017 | - | $58.75 M(+13.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $198.29 M(+18.2%) | $51.74 M(+12.3%) |
| Sep 2016 | - | $46.07 M(-13.1%) |
| Jun 2016 | - | $53.03 M(+11.8%) |
| Mar 2016 | - | $47.45 M(-6.4%) |
| Dec 2015 | $167.71 M(+33.7%) | $50.71 M(+23.1%) |
| Sep 2015 | - | $41.20 M(+7.3%) |
| Jun 2015 | - | $38.40 M(+2.7%) |
| Mar 2015 | - | $37.40 M(+7.1%) |
| Dec 2014 | $125.39 M(+49.2%) | $34.91 M(+6.9%) |
| Sep 2014 | - | $32.64 M(+8.6%) |
| Jun 2014 | - | $30.05 M(+8.1%) |
| Mar 2014 | - | $27.79 M(+11.1%) |
| Dec 2013 | $84.07 M(+49.5%) | $25.01 M(+17.5%) |
| Sep 2013 | - | $21.28 M(+12.4%) |
| Jun 2013 | - | $18.94 M(+0.5%) |
| Mar 2013 | - | $18.84 M(+13.5%) |
| Dec 2012 | $56.24 M(+60.5%) | $16.61 M(+11.4%) |
| Sep 2012 | - | $14.90 M(+21.3%) |
| Jun 2012 | - | $12.29 M(-1.3%) |
| Mar 2012 | - | $12.45 M(+33.4%) |
| Dec 2011 | $35.03 M(+40.2%) | $9.33 M(-0.0%) |
| Sep 2011 | - | $9.33 M(+3.1%) |
| Jun 2011 | - | $9.05 M(+23.7%) |
| Mar 2011 | - | $7.32 M(+20.1%) |
| Dec 2010 | $25.00 M(-20.0%) | $6.09 M(-17.8%) |
| Sep 2010 | - | $7.41 M(+27.0%) |
| Jun 2010 | - | $5.83 M(+3.2%) |
| Mar 2010 | - | $5.65 M(-34.4%) |
| Dec 2009 | $31.25 M(-25.3%) | $8.62 M(+20.3%) |
| Sep 2009 | - | $7.16 M |
| Dec 2008 | $41.83 M | - |
FAQ
- What is Pacira BioSciences annual total operating expenses?
- What is the all time high annual operating expenses for Pacira BioSciences?
- What is Pacira BioSciences annual operating expenses year-on-year change?
- What is Pacira BioSciences quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Pacira BioSciences?
- What is Pacira BioSciences quarterly operating expenses year-on-year change?
What is Pacira BioSciences annual total operating expenses?
The current annual operating expenses of PCRX is $402.99 M
What is the all time high annual operating expenses for Pacira BioSciences?
Pacira BioSciences all-time high annual total operating expenses is $402.99 M
What is Pacira BioSciences annual operating expenses year-on-year change?
Over the past year, PCRX annual total operating expenses has changed by +$6.38 M (+1.61%)
What is Pacira BioSciences quarterly total operating expenses?
The current quarterly operating expenses of PCRX is $107.76 M
What is the all time high quarterly operating expenses for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total operating expenses is $107.76 M
What is Pacira BioSciences quarterly operating expenses year-on-year change?
Over the past year, PCRX quarterly total operating expenses has changed by +$4.66 M (+4.52%)